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Abstract
The emergence of alternative medicines for AIDS in Asia and Africa was discussed at a satellite
symposium and the parallel session on alternative and traditional treatments of the AIDSImpact
meeting, held in Marseille, in July 2007. These medicines are heterogeneous, both in their
presentation and in their geographic and cultural origin. The sessions focused on the role of these
medications in selected resource poor settings in Africa and Asia now that access to anti-retroviral
therapy is increasing. The aims of the sessions were to (1) identify the actors involved in the
diffusion of these alternative medicines for HIV/AIDS, (2) explore uses and forms, and the way
these medicines are given legitimacy, (3) reflect on underlying processes of globalisation and
cultural differentiation, and (4) define priority questions for future research in this area. This article
presents the insights generated at the meeting, illustrated with some findings from the case studies
(Uganda, Senegal, Benin, Burkina Faso, China and Indonesia) that were presented. These case
studies reveal the wide range of actors who are involved in the marketing and supply of alternative
medicines. Regulatory mechanisms are weak. The efficacy claims of alternative medicines often
reinforce a biomedical paradigm for HIV/AIDS, and fit with a healthy living ideology promoted by
AIDS care programs and support groups. The AIDSImpact session concluded that more
interdisciplinary research is needed on the experience of people living with HIV/AIDS with these
alternative medicines, and on the ways in which these products interact (or not) with anti-retroviral
therapy at pharmacological as well as psychosocial levels.
Alternative medicines for AIDS in resource-poor 
settings: insights from exploratory 
anthropological studies in Asia and Africa
A large number of new treatments offered to people living
with HIV/AIDS (PLWA) have appeared over the last fif-
teen years in the therapeutic domain of AIDS. These med-
icines are particularly heterogeneous, both in their
presentation and in their geographic and cultural origin.
They constitute a group of products with a therapeutic aim
that occupies a space between the customary traditional,
popular and biomedical sectors of health care [1]. These
products often mix reference to biomedicine and science
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with notions of traditional health culture and nature in a
syncretic way. They consist mainly of herbs and nutri-
tional substances and are packaged as 'modern' pharma-
ceuticals: capsules, tablets, and solutions. The names of
these alternative treatments reflect their reference to bio-
medicine: Immunocomplex, Viralgic, Virjint, etc. Their
accompanying leaflets provide detailed information on
substance, as well as dosage, indications, and biomedical
efficacy claims. Their diffusion follows contemporary
paths in the global economy and makes use of new infor-
mation technologies. In this paper, we will use the term
"alternative" to consider a generic category including
medicines that recently appeared for AIDS which have not
been authorised by drug regulatory authorities, nor rec-
ommended by WHO. Other terms, such as neo-tradi-
tional or neo-phytotherapeutic, may be discussed for the
characterization of some of these treatments, related to
their local meanings or their social status.
The emergence of alternative medicines for AIDS in Asia
and Africa was discussed at a satellite symposium and the
parallel session on alternative and traditional treatments
of the AIDSImpact meeting, held in Marseille, in July
2007. We were especially interested in the role of these
medications since the introduction and rapid scale-up of
highly active anti-retroviral therapy (HAART) in resource
poor settings.
Twenty anthropologists and health researchers attended
the satellite session and presented exploratory findings
from Asia and Africa (Uganda, Senegal, Benin, Burkina
Faso, China and Indonesia). The aims of the satellite, the
results of which were presented at the parallel session [2],
were to (1) identify the actors involved in the diffusion of
these alternative medicines for HIV/AIDS, (2) explore uses
and forms of these medicines, and the way they are given
legitimacy, (3) reflect on underlying processes of globali-
sation and cultural differentiation, and (4) define priority
questions for future research in this area. We present here
the insights generated at the meeting, illustrated with
some findings from the studies that were discussed.
Modernization of traditional medicine
There has been an increased professionalisation and com-
mercialisation of traditional medicine in response to the
development of biomedicine. This trend is not specific to
AIDS and not necessarily a recent development. Social sci-
entists first noted this trend in the late 1980s: Charles Les-
lie [3] for example has shown how, in India, in response
to an increased authority of biomedicine and the globali-
sation of health markets, Unani and Ayurvedic medicine
production changed; and Afdhal and Welsch [4] described
the rise of 'modern' jamu in Indonesia. Jamu is the tradi-
tional term for Indonesian indigenous medicines usually
prepared from herbal medicines such as leaves, bark, roots
and flowers. Nowadays a multimillion dollar industry is
involved in the production of Ayurvedic and Unani med-
icines in India, and of jamu  in Indonesia. A rapidly
expanding assortment of powders, creams, pills, capsules
and cosmetics has been manufactured both in small cot-
tage industries as in large factories with increasingly
sophisticated technologies [3,4]. The modernization of
the manufacturing of these drugs has been accompanied
with more modern biomedical modes of presenting their
efficacy [5]. Under globalization, similar trends occurred
in other regions and these products diffused more rapidly.
At the seminars in Marseille, we discussed the ways in
which such alternative remedies operate in the therapeutic
domain of AIDS care. In the first decade of the AIDS epi-
demic there was no effective treatment for HIV/AIDS and
patients were faced with nearly certain premature death.
At that time, there were regular hypes offering hope for
life. But with the introduction of ART, alternative treat-
ments are now marketed for many additional purposes
too: to prevent AIDS, to kill viruses, to delay the need for
ART, to restore and enhance health while on ART, to treat
opportunistic infections, and to alleviate adverse side
effects of other treatments. Biomedical practitioners gen-
erally discourage the use of alternative medicines, fearing
interactions with ART and also through the concern that
patients may stop using ART.
Supplying alternative medicines for HIV/AIDS
At the AIDSImpact sessions Egrot and colleagues [6] pre-
sented findings on the supply of what they label "neo-tra-
ditional medicines" to refer to the boundary-crossing
nature of these treatments in West Africa. The "designers"
of the inventoried products are extremely heterogeneous.
In some cases these people are nationals of African coun-
tries who present themselves as healers. Some say they
have undertaken "research" on the basis of therapeutic
products that were already known locally. Others refer to
a dream revelation (classic in the universe of healers in
Africa) of a plant composition that is "efficacious" against
AIDS, while yet others speak of a divine revelation. Physi-
cians, scientists and academics are solicitated, brought
into involvement or spontaneously engage themselves in
the exploitation of neo-traditional products. The case
studies in West Africa show that other treatments, such as
Immunicomplex or Aloe Vera, originate in Europe and the
USA. Alternative medicines from Europe and the USA
occupy the same shelves in ordinary pharmacies as those
originating from Africa and China, often along with a few
'immune-boosting' food products (honey, olive oil). Spe-
cialized "bio", "natural health" and "health food" shops
make these products available to the more affluent. The
distributors and marketing men of these products also tar-
get health workers and clinics directly. The West Africa
case studies noted that health workers also have started toJournal of Ethnobiology and Ethnomedicine 2008, 4:16 http://www.ethnobiomed.com/content/4/1/16
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prescribe alternative products such as Immuboost
(NHi2T) or Viralgic (Pharma Concept) (see Figure 1).
A case study from Uganda showed how health workers
operating an anti-retroviral treatment program adopted a
locally available traditional ointment as an alternative
medication for skins problems of people living with HIV
and AIDS. The skin problems result from adverse effects of
ART or symptoms of opportunistic infections. The health
workers obtained the recipe from local traditional healers
(patients had told them that the cream works well), and
the patients help collect the ingredients. They 'repackage'
this traditional remedy into what is now called 'mobile
cream' (to make clear it is produced by the so called
'Mobile' ART program). One of the nurses reports:
"The mobile cream, which we ourselves prepare either at
our chief nurse's home or here at the office depending on
how busy we are at the office, is very efficacious for many
kinds of skin related conditions. We are quick to prescribe
it to the patients because we know it works and it is popular
among patients too because it works for them[7]."
Content analysis of drug information leaflets, advertise-
ments, product catalogues, and brochures distributed by
medical representatives in the West Africa case studies
[6,8] casts light on the range of effects that are attributed
to these drugs. Most commonly cited (biomedical) prop-
erties are immune-stimulation and antioxidant. Some
manufacturers suggest that the products have antiviral
properties as well. The antiviral dimension refers either to
the opportunistic infections such as herpes (mentioned
for example in the product information for Immuboost)
or eventually to the immunodeficiency syndrome itself.
Indeed, some products boldly claim anti-HIV activity as
well, and are marketed as natural ART (see Figure 2).
However, such efficacy claims are not static. The producer
of Virusinest (Nesto-Pharma) recently withdrew the anti-
viral claim, stating in its information leaflet: "the analyses
carried out among patients do not allow the anti-HIV
assertion to be upheld". There may be also inconsistencies
between various information sources. The brochure for
Viralgic (Pharma Concept) says that this is a product
which renders the virus undetectable, but the website of
the manufacturer presents the drug as immunostimulant
(result of trials published on the web site), and present the
product as treatment for opportunistic infections: "anti-
herpes...for healthy persons".
The demand for alternative medicines
A case study on Indonesia [9] dealt with the demand for
alternative medicines among PLWA. As Afdhal and
Welsch noted two decades ago, Indonesia has a thriving
market for jamu. Jamu are sold for a wide range of indica-
tions: common colds, influenza, headaches, aches and
pains, high blood pressure, beauty, improvements in sex-
ual performance, and recently to treat and prevent HIV-
related health problems. AIDS prevalence is below 1%
(i.e. this is a low prevalence area), but the disease is stig-
matised, because of its association with intravenous drug
use and prostitution. Hardon and her colleagues con-
ducted interviews with women and men who live with
HIV and use anti-retroviral therapy, mainly intravenous
drug users and their partners. All of them had better
health since taking these modern drugs. Nonetheless, all
of them see the need to take jamu as well. They do so in
Tobacoak's, West Africa Figure 2
Tobacoak's, West Africa.
Viralgic, West Africa Figure 1
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part out of their intention to live positively (i.e. eating and
sleeping well, and keeping a positive outlook on life), as
promoted by many of the support groups in which PLWA
participate. The respondents do not make distinctions
between modern medicines and jamu  in these health
maintenance and restoring practices. Rather they distin-
guish the drugs by their effects. They use popular jamu to
treat side effects of HAART, such as itchiness. These jamus
are not specifically promoted for HIV and AIDS in Indo-
nesia, perhaps partly because the disease is so stigmatised.
However one neo-traditional preparation stood out in the
narratives of our respondents as a product which can treat
HIV/AIDS: virgin coconut oil. Ceri, for example, started
using coconut oil shortly after she found out she was HIV-
positive. She says:
Actually, the effect is not only for your immune system. So,
I feel better, don't feel tired, and have more energy. I think
what influences most is self-suggestion. It's self-suggestion
that matters...
She stopped taking the oil because it is very expensive.
Mia (a 28 year old woman from Jakarta) was given virgin
coconut oil by a friend from Yogjakarta:
I got 70 boxes. A box contains 60 capsules. It took it every
day until I felt sick, but there was no effect. My CD4 level
did not increase. Three months, three months made me look
like a coconut you just needed to squeeze (laughing). I
became very oily. The good effect when you take VCO is
that your skin is silk smooth, your face is fairer and if you
take a shower, you don't need any lotion, because your skin
is naturally oily. That is the positive effect. Your hair is also
stronger.
But Buli, a 29-year-old ex-drug user from Karawang, one
of the most active members of the support group in Kara-
wang says:
The coconut oil, I was also suggested it, but I don't dare to
try it, because I thought I'm taking ARV now, so it's better
if I just continue.
In Indonesia, the drug sellers were not very willing to dis-
cuss the effects of VCO. They would acknowledge that
indeed these drugs are used by PLWA, or they would deny
knowing anything about the drugs. But their pharmacies
are full of advertisements for the products and they have
prominent positions on their shelves (see Figure 3).
Content analysis of the package information for VCO in
Indonesia revealed that they are marketed as real 'cure-
alls', i.e. to kill viruses and bacteria and/or strengthen the
immune system, efficacy claims that we also found in
West Africa. For example the package leaflet for Vicofit
(manufactured by Sumber Dinamis in Bogor) states that
the drug has "a high content of lauric acid which has anti-
virus, anti-bacterials and anti-protozoa properties." And
that it is "believed to help improve the health condition
of those with cholesterol, diabetes, coronary heart disease,
hepatitis C, HIV positive, cancer, prostate, uric acid, oste-
oporosis, influenza and weight problems". The package
for Virjint (produced by PT Vermindo International)
states that the medicine is safe for daily use and without
side effects. It lists two dosages: one for prevention (2 × 2
capsules per day) and another for treatment (2 × 3 cap-
sules per day). The leaflet stipulates that the indications
are:
- "to increase energy and body stamina
- to increase body resistance (Meningkatkan daya tahan
tubuh) against bacterial, viral and fungal pathogens
- to reduce weight
- anti-oxidant, anticancer, and anti-HIV
- to overcome uric acid, hypertension, stroke, heart dis-
ease, atherosclerosis, osteoporosis, influenza, hepatitis,
chickenpox, herpes, TB, diabetes, epilepsy, eczema, liver,
haemorrhoids, kidney, peradangan (burning sensation),
infection, degenerative disease."
The packages cite clinical research conducted elsewhere
(Philippines, USA) to give legitimacy to the products. For
example the leaflet of Holistic Virgin Coconut Oil states:
"Based on research conducted in the Philippines, Holistic
Virgin Coconut Oil is very effective to fight against SARS
and AIDS".
VCO, Indonesia Figure 3
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Conclusion
One of the key characteristics of alternative medicines in
Asia and Africa is that they move from one cultural and
geographic space to another, apparently without being
constrained by trade-barriers, or regulatory mechanisms.
Some governments promote the production and diffusion
of neo-traditional medicines. They do so for economic
reasons: alternative medicines are big business, but they
also do so for ideological reasons: neo-traditional medi-
cines reflect an attractive hybrid of modernity and
national heritage, providing a sense of national identity in
the globalized health economy [10]. The governments of
India, China, Indonesia, and some African countries sup-
port research programs to further advance these neo-tradi-
tional products, and facilitate market diffusion. While
registered pharmaceuticals are regulated heavily upon
market entry (proof of efficacy is assessed by national drug
regulatory authorities), this is not the case for alternative
medicines. ART programs, which are sponsored by the
same governments, usually discourage the use of alterna-
tive medicines, fearing the toxicity of the drugs, or that
these medicines will interact with anti-retroviral medica-
tion and lead to discontinuation of ART therapy [11].
Governmental agencies may have contradictory attitudes
towards the use of alternative medicines for AIDS, dis-
couraging it within ART programs and supporting it
within divisions of traditional medicine. An exception is
the Chinese government, which officially supports a com-
plementary medicine program for AIDS care and research
[12].
Mass-produced alternative medicines meet an increasing
demand for health products, a trend which has been
labelled the "commodification of health" [13,14]: from
the slums of Djakarta to rural settings in Burkina Faso,
people believe more and more that they need pharmaceu-
tical 'things' to protect their health and to treat illness
symptoms. People living with HIV and AIDS are particu-
larly uncertain about their health and their future: ART
may be accessible and improve health now, but they won-
der if this will be the case in the future. This uncertainty
makes them an attractive market for the 'best of both
worlds', alternative medicines, which come with asser-
tions of 'natural' safety and 'biomedical' efficacy [15].
However the case studies presented in Marseille suggest
that people especially want to use alternative medicines to
delay onset of ART, treat opportunistic infections, restore
health and alleviate adverse effects once on ART. Immune-
boosters are popular, though our case studies suggest that
PLWA are often ambivalent about alternative medicines
that claim anti-HIV efficacy.
The case studies make clear that the market of alternative
medicines for HIV/AIDS is dynamic. It adapts to progress
in biomedicine, which has produced potent anti-retrovi-
ral medications. In some cases, the efficacy claims for
alternative medicines reinforce a biomedical paradigm for
HIV/AIDS, and fit with a healthy living ideology pro-
moted by AIDS care programs and support groups. More
interdisciplinary research is needed on the experience of
people living with HIV/AIDS with these alternative medi-
cines, the ways in which the products and their represen-
tations move from one cultural setting to another, and on
the ways in which these products interact (or not) with
anti-retroviral therapy at pharmacological as well as psy-
chosocial levels. More research is also needed to assess the
economic impact of these therapies, since people seem to
be spending much on these 'other' medicines while ART is
provided for free. A blanket denial of the relevance of
these products for the quality of life of PLWA does not
make sense for patients, who need precise information
that make clear which products are likely to have negative
interactions with ART, and which ones could be benefi-
cial. Unfortunately research on the interactions between
alternative medicine and antiretroviral drugs is sparse
[11]. To be able to inform patients better, more clinical
research is needed on the benefits and risks of those alter-
native medicines that are perceived to be beneficial by
people living with HIV and AIDS.
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